Zuranolone

舒拉诺龙

Report date: 2025/12/23 11:16:27
NME

Base Information

Drug NameZuranolone
Drug Alias NameZurzuvaeSAGE-217S-812217BIIB-125S 812217 +[7] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGamma-aminobutyric acid A receptor modulators
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsBipolar II DisorderBipolar I DisorderDepressive Disorder, Major +[9] 
Global Approved IndicationsDepressive DisorderDepression, Postpartum
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/04
Country/TerritoryUnited StatesUnited KingdomSpain +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSage Therapeutics IncShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Netherlands BvDuke UniversityBiogen Inc +[5] 
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorDepressive DisorderDepression +[4] 
Inactive IndicationsBipolar II DisorderBipolar I DisorderSleep Initiation and Maintenance Disorders +[5] 

Other Information

ATC CodeN/A
Related LinksN/A